CLYM

Climb Bio, Inc. Common Stock
CLYM

Overview Fund Activity

71 hedge funds and large institutions have $278M invested in Climb Bio, Inc. Common Stock in 2024 Q3 according to their latest regulatory filings, with 31 funds opening new positions, 28 increasing their positions, 7 reducing their positions, and 7 closing their positions.

New
Increased
Maintained
Reduced
Closed
Holders
71
Holders Change
+24
Holders Change %
+51.06%
% of All Funds
1.03%
Holding in Top 10
1
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-50%
% of All Funds
0.01%
New
31
Increased
28
Reduced
7
Closed
7
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

1
BlackRock
1
BlackRock
New York
$9.5M
2
Vanguard Group
2
Vanguard Group
Pennsylvania
$7.76M
3
ABG
3
Ally Bridge Group
New York
$6.26M
4
T. Rowe Price Associates
4
T. Rowe Price Associates
Maryland
$3.43M
5
Point72 Asset Management
5
Point72 Asset Management
Connecticut
$3.01M

Top Sellers

1
DTC
1
Deep Track Capital
Connecticut
$11M
2
Adage Capital Partners
2
Adage Capital Partners
Massachusetts
$0
3
SB
3
Samsara BioCapital
California
$13.3M
4
Walleye Capital
4
Walleye Capital
New York
$0
5
AAA
5
Affinity Asset Advisors
New York
$7.64M
Name Holding Trade Value Shares
Change 		Shares
Change %
PAMP
76
Polar Asset Management Partners
Ontario, Canada
– -$76.7K -10,781 Closed
TSS
77
Two Sigma Securities
New York
– -$75.5K -10,619 Closed
1 2 3
4